Nano-Enabled Therapeutics: Novel Strategies for Preeclampsia Treatment

Min Wu, Xiaojuan Zhang, Xue Li, Chuanchuan HeInternational Journal of Nanomedicine 2026 · DOI

Abstract

Preeclampsia (PE), a pregnancy-specific disorder characterized by hypertension and placental dysfunction, remains a leading cause of maternal and fetal morbidities worldwide. Recent advances in nanomedicine offer promising therapeutic strategies by targeting placental pathologies. Studies have demonstrated that in PE mouse models, the regulation of key disease-related genes (such as sFlt1 and VEGF) using siRNA- or mRNA-loaded carriers (eg, lipid nanoparticles, exosomes, or elastin-like polypeptides) can effectively alleviate PE symptoms. This review summarizes the progress in nanoparticle-based therapies for PE, discusses challenges such as scalability and clinical translation, and highlights the potential of nanomedicine to revolutionize PE management.

Introduction

Preeclampsia (PE) is a complex, multisystem disorder affecting 3–8% of pregnancies worldwide. It is characterized by the sudden onset of hypertension and placental dysfunction, often leading to severe maternal and fetal complications. Currently, the only definitive treatment is the delivery of the placenta, which frequently results in iatrogenic preterm birth.

The pathophysiology of PE involves a two-stage process: initial defective placental vascularization leading to hypoxia, followed by the release of antiangiogenic factors—most notably soluble fms-like tyrosine kinase-1 (sFlt1)—into the maternal circulation. This excess sFlt1 neutralizes growth factors like VEGF, causing systemic endothelial damage. The challenge for drug delivery is twofold: reaching the placenta specifically to avoid liver sequestration and ensuring therapeutic agents do not cross the placental barrier to cause developmental toxicity in the fetus.

Nanocarrier Platforms for Gene and Drug Delivery

Recent advances in nanomedicine have introduced targeted delivery systems designed to address these placental pathologies while minimizing risks to the fetus. Four primary nanocarrier platforms have emerged as frontrunners in this field:

  • Lipid-Based Nanocarriers (LNPs & Liposomes): These are highly effective for encapsulating nucleic acids like mRNA or siRNA. By engineering the lipid composition, researchers can promote "endogenous targeting," where the particles adsorb specific blood proteins that naturally home to the placenta.
  • Polymer-Based Nanocarriers: Utilizing materials such as PAMAM dendrimers or chitosan, these carriers offer high programmability. Their surface can be functionalized with ligands like chondroitin sulfate A (CSA) to specifically bind to placental trophoblasts.
Figure 1: Payloads such as siRNA and mRNA encapsulated in lipid- and polymer-based nanocarriers.

Targeting Strategies and Specialized Carriers

Beyond lipid and polymer systems, protein and exosome-based carriers provide unique advantages for placental therapy, particularly regarding safety and biocompatibility.

  • Protein-Based Nanocarriers: Elastin-like Polypeptides (ELPs) are particularly noteworthy for their "maternal sequestration" capability. Due to their large hydrodynamic radius, they are unable to cross the placental barrier, ensuring that therapeutic payloads remain within the maternal/placental compartment.
  • Exosome-Based Nanocarriers: These naturally occurring vesicles, often derived from mesenchymal stem cells, offer innate biocompatibility and the ability to modulate immune responses at the maternal-fetal interface.
Figure 2: Placental targeting using protein-based and exosome-based nanocarriers.

Therapeutic Outcomes and Clinical Potential

Preclinical studies in rodent models have demonstrated the efficacy of these platforms in reversing PE pathology. Key breakthroughs include:

  • Gene Silencing: Anti-sFlt1 siRNA delivered via LNPs has significantly reduced maternal blood pressure and proteinuria in rat and mouse models.
  • Angiogenic Balance: Delivery of VEGF mRNA via optimized LNPs has been shown to restore placental vasculature and improve fetal weight.
  • Immune Modulation: Targeted LNPs delivering IL-4/IL-13 mRNA have successfully polarized placental macrophages toward a pro-healing M2 phenotype, reducing local inflammation.
  • Bypassing the Liver: Innovative LNP designs have achieved a >100-fold increase in placental tropism by favoring the adsorption of specific proteins like $\beta$2-glycoprotein I, successfully diverting the dose away from the maternal liver.

Challenges and Future Directions

While the transition from reactive symptom management to targeted nanomedicine is promising, several hurdles remain for clinical translation. Scalability of complex polymer and exosome systems is a significant concern compared to the established manufacturing pathways for LNPs. Furthermore, while "placenta-tropic" designs are improving, significant off-target accumulation in the maternal liver and spleen still occurs.

Future research is directed toward "environment-responsive" systems that only release payloads under the specific acidic or hypoxic conditions of the preeclamptic placenta. Ultimately, bridging the gap between rodent models and human clinical trials remains the primary challenge in obstetric nanomedicine.

Keywords: preeclampsia, nanocarrier, placenta, sFlt1

Summary updated

Abstract

Preeclampsia (PE), a pregnancy-specific disorder characterized by hypertension and placental dysfunction, remains a leading cause of maternal and fetal morbidities worldwide. Recent advances in nanomedicine offer promising therapeutic strategies by targeting placental pathologies. Studies have demonstrated that in PE mouse models, the regulation of key disease-related genes (such as sFlt1 and VEGF) using siRNA- or mRNA-loaded carriers (eg, lipid nanoparticles, exosomes, or elastin-like polypeptides) can effectively alleviate PE symptoms. This review summarizes the progress in nanoparticle-based therapies for PE, discusses challenges such as scalability and clinical translation, and highlights the potential of nanomedicine to revolutionize PE management. Keywords: preeclampsia, nanocarrier, placenta, sFlt1
BibTeX
@article{wu2026nano,
  author = {Min Wu and Xiaojuan Zhang and Xue Li and Chuanchuan He},
  title = {{Nano-Enabled Therapeutics: Novel Strategies for Preeclampsia Treatment}},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  doi = {10.2147/ijn.s578148},
}
Figure